Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Vertex Pharmaceuticals (NASDAQ ... company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important milestones in its growth strategy.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical ... The company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Journavx halts pain signaling in the peripheral ... believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...

Vertex Pharmaceuticals generated more than $11 ... making them drugs many patients and doctors aim to avoid. The FDA granted Journavx (formerly known as suzetrigine), a non-opioid painkiller ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Vertex Pharmaceuticals Inc.’s new non-opioid ... The medication, called Journavx, was approved in the United States in January. The financial success of new drugs largely depends on how they ...